Bjorn T. Gjertsen
Universitetet i Bergen
H-index: 64
Europe-Norway
Top articles of Bjorn T. Gjertsen
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study | Leukemia | Gianantonio Rosti Tim H Brümmendorf Björn T Gjertsen Pilar Giraldo-Castellano Fausto Castagnetti | 2024/1 |
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century | Blood cancer journal | Kari Hemminki Frantisek Zitricky Asta Försti Mika Kontro Bjorn T Gjertsen | 2024/3/14 |
How to discover the exceptional venetoclax responders in AML/MDS? | British Journal of Haematology | Bjørn Tore Gjertsen | 2024/1 |
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib-interim results from the … | Leukemia | Hjalmar Flygt Stina Söderlund Johan Richter Susanne Saussele Perttu Koskenvesa | 2024/2/28 |
Assessment of postoperative circulating tumour DNA to predict early recurrence in patients with stage I–III right-sided colon cancer: prospective observational study | BJS open | Kristin B Lygre Rakel B Forthun Trude Høysæter Sigrun M Hjelle Geir E Eide | 2024/2 |
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib–interim results from the DAstop2 trial | Leukemia | Hjalmar Flygt Stina Söderlund Johan Richter Susanne Saussele Perttu Koskenvesa | 2024/1/26 |
Monosomy 7/del (7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia | Blood Advances | Samuli Eldfors Joseph Saad Nemo Ikonen Disha Malani Markus Vähä-Koskela | 2024/4/9 |
Hever kvaliteten på behandling av kreft | Tidsskrift for Den norske legeforening | Åslaug Helland Eli Sihn Samdal Steinskog Egil Støre Blix Åsmund Flobak Sigmund Brabrand | 2024/1/18 |
Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations | American journal of hematology | Alesia A Khan Daniel James Vibeke Andresen Julie Atkey Rachel Bradbury | 2024/4/3 |
Intradermal vaccination with vididencel in MRD+ AML-patients leads to increase in antigen presenting cells and T-cells to the injection site, visualized using imaging mass … | Blood | Oystein Sefland Reidun Kristin Kopperud Hester Van Zeeburg Jeroen Rovers Maria Omsland | 2023/11/28 |
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects | Annals of Hematology | Inge GP Geelen Stein-Erik Gullaksen Mette M Ilander Ulla Olssen-Strömberg Satu Mustjoki | 2023/6 |
P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA | HemaSphere | Ida Vänttinen Sari Kytölä Olli Dufva Monica Hellesøy Stein-Erik Gullaksen | 2023/8/1 |
WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy | Leukemia | Yngvar Fløisand Mats Remberger Iris Bigalke Dag Josefsen Helen Vålerhaugen | 2023/9 |
AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational … | Blood | Niklas Beumer Jonas S Waizenegger Michael Heuser Jörg Chromik Grerk Sutamtewagul | 2023/11/2 |
Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with … | Blood | Hester Van Zeeburg Eva Wagner Drouet Uwe Platzbecker Tobias AW Holderried Catharina Van Elssen | 2023/11/28 |
Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial | Blood, The Journal of the American Society of Hematology | Lok Lam Ngai Diana Hanekamp Fleur Janssen Jannemieke Carbaat-Ham Maaike AMA Hofland | 2023/5/25 |
PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML | HemaSphere | Brunangelo Falini Maria Paola Martelli Riccardo Rossi Fabio Facchetti Stefania Zini | 2023/8/1 |
P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH … | HemaSphere | Hester Van Zeeburg Satwinder Kaur Singh Eva Wagner-Drouet Uwe Platzbecker Tobias Holderried | 2023/8/1 |
Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies | Blood | Lok Lam Ngai Coen R Veenstra Patrycja Gradowska Angèle Kelder Willemijn Scholten | 2023/11/2 |
Phase Ib/II Study (NCT02488408/BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome … | Blood | Sonja Loges Michael Heuser Jolanta Chromik Grerk Sutamtewagul Silke Kapp-Schwoerer | 2023/11/28 |
Co-Authors
